Based on the strategy of synthetic lethality and drug repurposing, we conducted a drug repurposing screening in an approved drug library in ARID1A isogenic CRC cells and identified estramustine phosphate sodium (EMP) as a potent synthetic lethal candidate for ARID1A-deficient CRC cells. This evidence concerns the gene ARID1A and colorectal carcinoma.